Satellos Bioscience Inc. Stock Price

TSX:MSCL Community·CA$126.1m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

MSCL Share Price Performance

CA$0.69

-0.16 (-18.82%)

CA$0.69

-0.16 (-18.82%)

CA$0.69

Sat, 8 Nov 25

Share PriceCA$0.69

MSCL Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks

0 Rewards

View Full Analysis

Satellos Bioscience Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.12
: 0%
: 0%
: 0%

View Full Analysis

About MSCL

Founded: 2018
Employees: 16
CEO: Francis Gleeson
WebsiteView website: satellos.com

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.